Since in tumor cell lines, c-Met phosphorylation can result from EGFR activation [15], parallel inhibition of EGFR and c-Met could increase the clinical benefit due to synergistic effects of tivatinib and erlotinib or gefitinib. Here, MET is linked to neoplasm.